Volume 32, Number 6—June 2026
Synopsis
Outcomes of Hospitalized and Critically Ill Adults with Murine Typhus, Galveston, Texas, USA, 2019–2023
Matthew Pickich
, Puneet Singh, Efstathia Polychronopoulou, Shawn P. Nishi, Lucas S. Blanton, and Alexander G. Duarte
, Puneet Singh, Efstathia Polychronopoulou, Shawn P. Nishi, Lucas S. Blanton, and Alexander G. Duarte
Table 4
Comparison of treatment and outcomes of patients in study of outcomes of hospitalized and critically ill adults with murine typhus, Galveston, Texas, USA, 2019–2023*
| Treatment or outcome | Non-ICU, n = 86 | ICU, n = 33 | p value |
|---|---|---|---|
| Mean time to diagnosis, d (SD) | 3.6 (5.8) | 4.1 (4.4) | 0.063 |
| Median time to diagnosis, d (IQR) |
2 (1–3) |
3 (1–4) |
0.061 |
| Mean time to antibiotic, d (SD) | 1.6 (1.3) | 2.2 (2.1) | 0.264 |
| Median time to antibiotic, d (IQR) |
1 (1–2) |
2 (1–3) |
0.262 |
| Doxycycline | 0.145 | ||
| Yes, no. (%) | 82 (95.35) | 29 (87.9) | |
| Median doxycycline inpatient duration, d (IQR) |
4 (2–5) |
5 (4–7) |
<0.001 |
| Azithromycin | 0.127 | ||
| Yes, no. (%) | 11 (12.8) | 8 (24.2) | |
| Median azithromycin inpatient duration, d (IQR) |
3 (2–4) |
2 (2–3) |
0.489 |
| Vasopressors, no. (%) | <0.001 | ||
| Yes |
5 (5.8) |
12 (36.4) |
|
| CRRT, no. (%) | 0.021 | ||
| Yes |
0 |
2 (6) |
|
| Ventilation, no. (%) | <0.001 | ||
| Yes |
0 |
5 (15.2) |
|
| Mean hospital LOS, d (SD) | 4.8 (2.2) | 9.3 (8.4) | <0.001 |
| Median hospital LOS, d (IQR) | 4 (3–6) | 7 (5–9) | <0.001 |
*CRRT, continuous renal replacement therapy; IQR, interquartile ratio; LOS, length of stay.
Page created: April 29, 2026
Page updated: June 01, 2026
Page reviewed: June 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.